Clinical Trials
407 trialsNCT05599048 2026-05-27
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
University of California, San Francisco
Phase 1/2 Recruiting
NCT07226349 2026-05-27
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07414836 2026-05-27
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07128303 2026-05-26
Study of GS-5319 in Adults With Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT05981703 2026-05-22
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06589596 2026-05-22
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06598800 2026-05-22
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05170958 2026-05-15
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT05329103 2026-05-15
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Peel Therapeutics Inc
Phase 1 Recruiting
NCT05901285 2026-05-14
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Vaxiion Therapeutics
Phase 1 Recruiting
NCT07182591 2026-05-14
A Study of DS5361b in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT07587879 2026-05-14
mRNA-LNP
IntraAb, Inc.
Phase 1/2 Not yet recruiting
NCT04322006 2026-05-13
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Completed
NCT07582822 2026-05-13
JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC
Biotech Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05438329 2026-05-12
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Active not recruiting
NCT06625593 2026-05-11
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06685068 2026-05-08
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT04896697 2026-05-05
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Active not recruiting
NCT05038150 2026-05-05
Study of SGN1 in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT05103345 2026-05-05
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT04083976 2026-05-04
RAGNAR
Janssen Research & Development, LLC
Phase 2 Completed
NCT05824663 2026-05-04
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
Phase 1 Completed
NCT05580770 2026-05-01
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT07298772 2026-05-01
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT07300943 2026-05-01
Study in Advanced Solid Tumor Patients
Callio Therapeutics
Phase 1/2 Recruiting
NCT05300048 2026-04-30
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Faeth Therapeutics
Phase 1 Terminated
NCT06833008 2026-04-30
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT06927687 2026-04-29
Study of ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Active not recruiting
NCT05451602 2026-04-28
HEC169096 in Participants With Advanced Solid Tumors
Sunshine Lake Pharma Co., Ltd.
Phase 1/2 Recruiting
NCT05687682 2026-04-28
Safety of AM-928 Infusion in Advanced Solid Tumors
AcadeMab Biomedical Inc.
Phase 1 Recruiting
NCT06260514 2026-04-23
ACESOT-1051
Aprea Therapeutics
Phase 1 Recruiting
NCT05036291 2026-04-22
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Ningbo Newbay Technology Development Co., Ltd
Phase 1 Terminated
NCT04855656 2026-04-20
MYTHIC
Debiopharm International SA
Phase 1 Recruiting
NCT06597721 2026-04-17
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS
Phase 1 Recruiting
NCT07380334 2026-04-16
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Recruiting
NCT04886271 2026-04-15
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 2 Completed
NCT06233942 2026-04-15
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06220864 2026-04-14
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
Phase 1 Recruiting
NCT06470763 2026-04-14
EXPAND-1
Anaveon AG
Phase 1/2 Active not recruiting
NCT06143774 2026-04-13
Study of TRX-920 for Patients With Advanced Solid Tumors
TaiRx, Inc.
Phase 1 Recruiting
NCT06352359 2026-04-13
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Recruiting
NCT07408258 2026-04-13
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Not yet recruiting
NCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06635785 2026-04-09
BiPAVE-001
OncoC4, Inc.
Phase 1/2 Recruiting
NCT06911827 2026-04-07
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06422520 2026-04-06
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT07512583 2026-04-06
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06672185 2026-04-03
ARC101 in Advanced Solid Tumors
Third Arc Bio
Phase 1 Recruiting
NCT07508761 2026-04-02
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2 Not yet recruiting
NCT06953323 2026-03-27
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting